SK Biopharmaceuticals (326030) stock
KOSPI · Pharmaceuticals
As of Nov 16, 11:28 AM KST
Events and reference metrics · 1
- Market cap
- KRW 6.9 trillion
- As of Nov 16, 2026
- P/E
- 17.17x
- Trailing twelve months
- P/B
- 6.74x
- Latest reported equity
- P/S
- 7.99x
- Trailing twelve months
- ROE
- 39.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 6.9 trillion
- As of Nov 16, 2026
- P/E
- 17.17x
- Trailing twelve months
- P/B
- 6.74x
- Latest reported equity
- P/S
- 7.99x
- Trailing twelve months
- ROE
- 39.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
17.17x
P/B
6.74x
P/S
7.99x
Earnings and dividend metrics▾
Earnings
EPS
KRW 5,120
Earnings per share
BPS
KRW 13,047
Book value per share
ROE
39.2%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 5,120 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 13,047 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 39.2%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 247.4 billion | KRW 97.1 billion | KRW 85.1 billion | +40.3% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 227.9 billion | KRW 89.8 billion | KRW 102.7 billion | +57.8% |
| Q4 2025Consolidated · Filed Mar 18, 2026 | KRW 194.4 billion | KRW 46.3 billion | KRW 132.7 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 191.7 billion | KRW 70.1 billion | KRW 71.4 billion | +40.4% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 176.3 billion | KRW 61.9 billion | KRW 29.5 billion | +31.6% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 144.4 billion | KRW 25.7 billion | KRW 19.6 billion | +26.7% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 18, 2026 | KRW 706.7 billion | KRW 203.9 billion | KRW 253.3 billion | +29.1% |
| FY2024Consolidated · Filed Mar 18, 2025 | KRW 547.6 billion | KRW 96.3 billion | KRW 227 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 4.85%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 1 billion
- Previous 20-day average 6.30%
- Net short position
- 393,370 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,116,839 shares
- As of Nov 13, 2026 · 2.70% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 4.85% | KRW 1 billion |
| Nov 12, 2026 | 4.72% | KRW 1.16 billion |
| Nov 11, 2026 | 4.36% | KRW 1.24 billion |
| Nov 10, 2026 | 2.77% | KRW 920 million |
| Nov 9, 2026 | 3.45% | KRW 1.33 billion |
| Nov 6, 2026 | 1.60% | KRW 710 million |
| Nov 5, 2026 | 1.98% | KRW 2.44 billion |
| Nov 4, 2026 | 4.54% | KRW 1.37 billion |
| Nov 3, 2026 | 4.72% | KRW 1.22 billion |
| Nov 2, 2026 | 6.26% | KRW 440 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Preliminary Consolidated Operating Results (Fair Disclosure)Nov 5, 2026 · Preliminary EarningsEnglish
- Material Management Information(Korean)Nov 4, 2026
- Single Sales or Supply Contract(Korean)Sep 23, 2026 · Supply Contract
- Material Management Information for Investment Decisions(Korean)Sep 17, 2026 · Material Management Information
- Report on Changes in Shares Held by the Largest Shareholder and Related Parties(Korean)Sep 15, 2026 · Largest Shareholder Holding Change
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Sep 15, 2026 · Insider Ownership Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Sep 15, 2026 · Insider Ownership Report
- Single Sales or Supply Contract(Korean)Sep 14, 2026 · Supply Contract
Filings with a published English version open in English; the rest link to the Korean original.
SK Biopharmaceuticals (326030) stock information
KOSPI
SK Biopharmaceuticals (326030) is listed on KOSPI. Its market capitalization is about KRW 6.9 trillion. On trailing-twelve-month earnings the P/E ratio is 17.17, and the P/B ratio is 6.74. Return on equity is 39.2%. These figures are computed in-house from official filings and are reference information only.
SK Biopharmaceuticals — frequently asked questions
- What is the P/E ratio of SK Biopharmaceuticals (326030)?
- On a trailing-twelve-month basis, 326030 trades at a P/E ratio of 17.17. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of SK Biopharmaceuticals?
- 326030 has a market capitalization of about KRW 6.9 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.